BAY-1895344

• CAT Number: I003980
• CAS Number: 1876467-74-1
• Molecular Formula: C20H21N7O
• Molecular Weight: 375.43
• Purity: ≥95%
• Synonyms: BAY-1895344; BAY 1895344; BAY1895344.;(R)-3-methyl-4-(4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl)morpholine
• Target: ATR inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term or -20 °C for long term
• IUPAC Name: (3R)-3-methyl-4-[4-(2-methylpyrazol-3-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridin-2-yl]morpholine
• InChI: InChI=1S/C20H21N7O/c1-13-12-28-10-9-27(13)18-11-15(17-5-8-23-26(17)2)14-3-6-21-20(19(14)24-18)16-4-7-22-25-16/h3-8,11,13H,9-10,12H2,1-2H3,(H,22,25)/t13-/m1/s1
• InChIKey: YBXRSCXGRPSTMW-CYBMUJFWSA-N
• SMILES: C[C@@H]1COCCN1C2=NC3=C(C=CN=C3C4=CC=NN4)C(=C2)C5=CC=NN5C

BAY-1895344 (Cat No.:I003980) is a potent and selective ATR (ataxia-telangiectasia and Rad3-related) inhibitor. It inhibits the activity of ATR kinase, which plays a crucial role in the DNA damage response pathway. BAY-1895344 has demonstrated potent anti-tumor efficacy in monotherapy, suggesting its potential as a standalone treatment for certain cancers. Additionally, it has shown strong combination potential with Radium-223 dichloride, a targeted alpha therapy used in the treatment of metastatic castration-resistant prostate cancer. This combination approach may enhance the therapeutic effects and improve patient outcomes.